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Abstract
Here, we report on the outcome of the 2nd International Danube Symposium on advanced
biomarker development that was held in Vienna, Austria, in early 2018. During the meeting,
cross-speciality participants assessed critical aspects of non-invasive, quantitative biomarker
development in view of the need to expand our understanding of disease mechanisms and the
definition of appropriate strategies both for molecular diagnostics and personalised therapies.
More specifically, panelists addressed the main topics, including the current status of disease
characterisation by means of non-invasive imaging, histopathology and liquid biopsies as well as
strategies of gaining new understanding of disease formation, modulation and plasticity to large-
scale molecular imaging as well as integrative multi-platform approaches. Highlights of the 2018
meeting included dedicated sessions on non-invasive disease characterisation, development of
disease and therapeutic tailored biomarkers, standardisation and quality measures in
biospecimens, new therapeutic approaches and socio-economic challenges of biomarker
developments. The scientific programme was accompanied by a roundtable discussion on
identification and implementation of sustainable strategies to address the educational needs in
the rapidly evolving field of molecular diagnostics. The central theme that emanated from the
2nd Donau Symposium was the importance of the conceptualisation and implementation of a
convergent approach towards a disease characterisation beyond lesion-counting Blumpology^
for a cost-effective and patient-centric diagnosis, therapy planning, guidance and monitoring.
This involves a judicious choice of diagnostic means, the adoption of clinical decision support
systems and, above all, a new way of communication involving all stakeholders across
modalities and specialities. Moreover, complex diseases require a comprehensive diagnosis by
converging parameters from different disciplines, which will finally yield to a precise therapeutic
guidance and outcome prediction. While it is attractive to focus on technical advances alone, it is
important to develop a patient-centric approach, thus asking BWhat can we do with our expertise
to help patients?^
Key words: Biomarker, Health economics, Ethics, Liquid biopsies, Molecular imaging, Molecular
and digital pathology, Omics technologies, Patient management, Pharmacology, Theranostics,
Treatment, Sample quality
Introduction
The 2nd Danube Symposium on advanced biomarker develop-
ment was held over March 14–17, 2018, in Vienna. This
symposium was dedicated towards building a framework centred
on the philosophy of convergent engagement (http://
news.mit.edu/2011/convergence-0104) of multiple stakeholders
in the development and implementation of quantitative, data-
driven biomarkers.Multiple definitions for biomarkers exist, but it
is understood that reproducible, quantitative and visual biomarkers
are required for the practice of personalised diagnosis and
treatment [1, 2] (Fig. 1).
The 1st Danube Symposium—held in Vienna during Septem-
ber 28–31, 2016—was one the first of its kind to be specifically
devoted to merging complementary expertise in cancer manage-
ment from molecular pathology, nuclear medicine and clinical
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pharmacology. At the time, the programme included a Bbasic
track^, which aimed at introducing the partnering
specialities—molecular pathology, nuclear medicine and clinical
pharmacology, and a Bclinical application track^ with a focus on
prostate cancer. In contrast, the format of the second symposium
was modified to provide more in-depth presentation and
discussion of different platforms for biomarker identification,
development, standardisation and implementation as well as
societal and ethical aspects of biomarker-driven personalised
medicine (http://www.applied-diagnostics.eu).
The 2018 programme included a series of key presentations,
moderated panel discussions, roundtable and rapid-fire presen-
tations the current status of biomarker availability and validity.
This included the applicability of liquid biopsies and tissue
samples, particularly in light of spatio-temporal tumour
heterogeneity as well as access to and sourcing of biobanks.
The status of application of existing biomarkers and the
development of new compounds for novel therapeutic ap-
proaches were also discussed, whereby a particular focus was
given to agents targeting the immune system and their
translation into the clinic. Finally, a third track brought together
panelists who highlighted a frequently under-represented topic:
socio-economic and ethical challenges in biomarker develop-
ment and patient care. Here, we summarise the main topics and
outcomes of the discussions. We will indicate progress in key
aspects of biomarker-related research as follows: progress (↑),
steady state (↔) and regression (↓) (Table 1).
The 2018 meeting started with an invited presentation by
Dr. Rodney Hicks from the Peter MacCallum Cancer Centre
in Melbourne on the BChallenges and Opportunities for
Molecular Imaging and Theranostics in the Era of Precision
Medicine^, which was entitled BLost in Translation^, thus
referring to a popular clip (https://www.youtube.com/
watch?v=yR0lWICH3rY), that is synonymous of the current
state communications between clinicians and researchers in
the field of molecular medicine. In essence, similar
perspectives were raised by other experts in the field who
argued that imaging physicists, for example, need to move
beyond simple system engineering and performance mea-
surements towards understanding biology and building their
methodological research on biological pre-conditions and
clinical questions [3], or who claimed failure in speaking the
same language when communicating over the imaging needs
for oncology.
Dr. Hicks highlighted how our understanding of oncol-
ogy has transitioned only recently from the assessment of its
morphological characteristics on both imaging and histopa-
thology to detailed genomic interrogation. In view of the
human cancer genome programme [4], he argued that it has
become clear that, rather than focusing on cancers by their
organ of origin, individual genomic drivers are critical to the
behaviour and, hence, the prognosis and treatment of
specific cancer subtypes. Accordingly, it has become
increasingly important to characterise the biological features,
indeed the specific genomic drivers of cancer in an
individual patient in order to select more specifically
targeted therapies that will deliver rational and efficient
cancer control. This process has been labelled Bprecision
medicine^.
As the oncology community becomes better informed
about the hallmarks of cancer, there is an opportunity to
leverage these features of biology as both diagnostic and
therapeutic targets (http://news.mit.edu/2011/convergence-
0104). Through imaging, it becomes feasible to identify
variations in target expression throughout the body but not
the genomic basis of such variation. Tissue and serum
biomarkers, on the other hand, can start to deconvolve these
processes but cannot localise the site of disease. Biopsy
specimens are also limited to assessment of a small portion
of the potential disease burden and may not be representative
of all disease sites. However, by combining these tech-
niques, it becomes possible to draw links between phenotype
and genotype, which must be inextricably linked [5]. This
can be performed prior to the onset of treatment in order to
Fig. 1. Illustration of the use of a biomarker as a tool for the
development of a predictive, preventive and patient-centric
(aka personalised) model of care.
Table 1. Key to current status of biomarker development
↑ Documented evidence of improvement in science and methodology
↗ Suggestion of improvement in methodology, but requires further investigation
↔ No change, but satisfactory status since previous workshop
↘ Little advancement in science and methodology despite previous recognition of need for improvement
↓ Less clear evidence than previously suggested
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optimise therapeutic selection but also early during treatment
to assess target modulation.
However, heterogeneity is ubiquitous in cancer and poses
a major challenge to any single therapeutic modality. As a
consequence, combinatorial therapies will be required.
Molecular imaging, targeted biopsy and genomic evaluation
of circulating tumour deoxyribonucleic acid (DNA) already
provide complementary methods to characterise cancer for
selection and sequencing of cancer therapies and will
become vital tools for monitoring the response of cancer to
therapy and its evolution if not eradicated by initial
treatment efforts. He concluded by saying that the opportu-
nity that molecular imaging provides is mainly in identifying
non-responding sites of disease as sources of relapse and
metastasis, which ultimately lead to lethality of cancers.
Therefore, the assessment of the mechanism of resistance in
such disease can then be specifically interrogated by either
targeted biopsy or the use of liquid biopsy, providing
information that might inform alternative or additional
treatment options as well as minimally invasive biomarker
candidates for diagnostic applications in parallel to imaging
approaches.
Tracks
Building on feedback from the first symposium and ongoing
debates in the field, the programme of this second
symposium was broken into three serial tracks that
highlighted key aspects of biomarker development: disease
characterisation (track 1), biomarker handling and treatment
(track 2) and, finally, evidence and ethical aspects (track 3).
Track 1: Disease Characterisation
Disease characterisation on a molecular level and the
identification of treatable targets as well as clonal evolution
and resistance play an increasingly important role. Modern
diagnostic and therapeutic biomarkers are frequently identi-
fied from large biobanks containing human tissue or liquid
samples or are derived from thousands of clinical data sets,
applying bioinformatics or other artificial intelligence (AI)
approaches. Novel strategies also focus on the generation of
patient-derived cell (PDC) culture, three-dimensional spher-
oid and organoid avatars from human tissue samples in vitro
or humanised mice in vivo [6]. This raises multiple ethical
and legal questions that have to be resolved before wider
adoption.
The overarching goal of any disease characterisation is to
collect a sufficient number of reliable and reproducible data
points (aka biomarkers) for a personalised approach to each
patient in need of a therapy, the right diagnosis at the right
time for the right patient yielding the most efficient
treatment (Fig. 1). Until a few years ago, over 150,000
studies have been published that document thousands of
claims for promising biomarkers, but only a hundred or so
have been validated for clinical use [7]. The reason for this
high attrition rate is seen by many as a failure of researchers
to embrace a collaborative, systems-based approach to
biomarker development. This track aimed at highlighting
biomarker diversity in view of the need to harmonise their
sourcing with high quality. General progress indicators for
biomarker development in disease characterisation are
summarised in Table 2.
Liquid Biopsy Versus Tissue Probes
Versus Molecular Imaging
Liquid Biopsy
The Issues Tumour cells may vary in tissue and genetic
composition across lesions within a single patient, and they
may change their profile during the course of therapy or
monitoring [8–11]. Thus, it has been suggested to analyse
circulating tumour cells (CTCs) and tumour-derived prod-
ucts in the context of liquid biopsy [12–14]. Unlike physical
fine-needle biopsies, liquid biopsies are quick, minimally
invasive and comprehensive in tissue profiling, assuming a
high sensitivity and reproducibility of the liquid analysis
work-up.
Recent Advances Recent advances allow for application of
liquid biopsy tests for early cancer detection [13]. Cohen
et al. [15] reported a novel test, enabling detection and
localisation of eight most common cancers. Although
sensitivity of the test is up to 98 % for ovarian cancer, the
average sensitivity of the test was only 70 % with a
specificity of 99 % [15, 16].
CTC can be characterised as anoikis-resistant, genetically
and phenotypically heterogeneous cells with ability to
Table 2. Track 1: progress indicators for biomarker development in disease characterisation
Feature 2016 2018
Clinical adoption of liquid biopsies as indicators of disease onset and cancer therapy response ↔ ↗
Tissue-based genomic analysis as part of routine patient management ↓ ↓
Molecular imaging providing sufficiently validated biomarkers ↘ ↘
Use of biobanks for large-scale biomarker development ↘ ↘
Radiomics for improving early treatment response assessment ↓ ↘
Data mining using electronic health records ↓ ↘
Interactomics as a clinical concept ↓ ↓
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invasion and metastasis-initiating potential [12]. CTC anal-
ysis is a validated prognostic test in metastatic breast, colon
and prostate cancers [17–19]. Moreover, the presence of
CTCs measured at baseline before neoadjuvant therapy is
predictive for survival independently from pathological
complete response [20]. Besides CTCs, circulating tumour
DNA (ctDNA) is another liquid biopsy analytic widely
utilised for monitoring of progression and therapy response
[13, 21–24]. Among circulating non-coding nucleic acids,
miRNAs are the most prominent analytics [25–28].
Future Challenges Biomarkers discovered and validated
on cohorts of late-stage patients might be under-represented
in early-stage/high-risk individuals [13]. Furthermore, aging-
associated appearance of mutations in cancer-associated
genes represents another hurdle in application of early
detection tests [29]. Challenges in CTC detection are related
to biological properties of the cells [30, 31]. Despite recent
advances of the development and application of liquid
biopsy tests, one of the major issues remains standardisation
of the pre-analytical parameters [28].
Tissue Probes and Tissue-Based Genomics
The Issues In oncology, clinical decision-making is mostly
based on laboratory tests and histopathological analyses.
Although these techniques are widely used, the total cost
adds up to only around 2 % of healthcare costs worldwide.
In contrast, lab tests drive around 80 % of total healthcare
costs for therapies. Laboratory tests are widely available,
easily accessible and highly sensitive. On the other hand, in
the context of novel concepts of targeted therapies, imple-
mentation of workflows that identify highly specific proof of
target structural alterations (mutations) becomes important.
Recent Advances Over the past decade, molecular diag-
nostic laboratories have moved from single gene assays to
large-scale genomic analyses, which allow for more sensi-
tive and simultaneous detection of many gene regions, thus
enabling testing of multiple genetic alterations even with
limited amounts of starting DNA/RNA. Most laboratories
utilise targeted sequencing panels for lower sequencing costs
and shorter turn-around times. In addition, targeted sequenc-
ing panels allow for higher sequencing coverage of genomic
regions of interest, which is critical for the identification of
somatic mutations in clinical samples that are typically
composed of both neoplastic and non-neoplastic cells. These
approaches have been successfully implemented to evaluate
gene mutations relevant for Bsolid tumors^ and
Bhematologic malignancies^ using small amounts of starting
material, such as fine-needle aspirations [32].
Future Challenges Many potentially targetable genetic
alterations are rare and lack sufficient supportive evidence
from well-designed clinical trials. A large inter-institutional
database would enable healthcare professions to collate and
share the molecular and clinical data, as attested by the
efforts of the Molecular Analysis for Therapy Choice
(MATCH) trial for adults and children supported by the
National Cancer Institute, and the Target Agent and
Profiling Utilization Registry (TAPUR) trial conducted by
the American Society of Clinical Oncology (ASCO) [33].
Furthermore, the role of the tissue pathologist in the
implementation and reporting of liquid biopsies needs to be
clarified. Figure 2 demonstrates a framework by which
various biosamples, molecular testing platforms and their
integration may contribute to the clinical decision-making
process for patients with lung cancer.
Molecular Imaging: a Non-invasive Tool for
Disease Characterisation at the Forefront of
Precision Medicine
The Issues Clinical molecular imaging applications, such
as those promoted through positron emission tomography
(PET), have been dominated by the relatively non-specific
tracer 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), a glu-
cose analogue. However, the intrinsic innovation potential of
PET is clearly in the ability to fully quantify metabolic and
signaling pathways non-invasively [2]. More recently,
innovation in PET detector technology and system design
has been demonstrated through the introduction of novel
detector and readout concepts that helped improve the
spatial and temporal resolution as well as the combination
of PET with computed tomography (PET/CT) or PET with
magnetic resonance imaging (PET/MRI) [34–37]. To date,
this innovation path has been seemingly more convincing
than that of disease-specific imaging probes ready for
routine clinical use, thereby attesting more to rather extreme
hurdles along the way of probe validation and market
authorisation rather than developing probes that target
specific metabolic of signaling pathways.
Recent Advances Over the past decade, radiopharmaceuti-
cals for the diagnosis of Morbus Alzheimer and somatostatin
receptor expressing neuroendocrine tumours and prostate
cancers have become available [38].
Future Challenges With the advent of costly yet potent
immunotherapies, molecular targeted therapies and combi-
nations thereof, the field of cancer diagnostics, disease
monitoring and therapy guidance has to undergo a paradigm
shift, as supported by multi-modality PET/CT and PET/MR
imaging [36, 37].
However, current clinical diagnostic workflows are
trimmed towards simplification and often ignore the wealth
of quantitative data yielded by PET, including in-depth
information about pharmacokinetics [2]. So far, the costs of
non-invasive imaging—which is marginal compared to the
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costs of modern combinatorial therapies that can be as high
as US$400,000 per patient. Unfortunately, the imaging field
is not ready yet to provide the desired diagnostic or
prognostic information for state-of-the-art and clinically
applied immunotherapies (involving checkpoint inhibitors,
antibodies or cell-based therapies), molecular targeted
therapies or the combination thereof.
Innovation in Biobanking
The Issues
To understand the combined effects of genetic and
environmental factors on health and diseases, a broad
spectrum of samples and analytes has to be investigated
by a variety of omics technologies. The development of
analytical technologies goes hand in hand with the
development of quality requirements of biospecimen in
order to guarantee proper test performance and reproduc-
ible data. Furthermore, biosamples have to be associated
with detailed information on the patient or sample donors,
sample-related meta-data as well as data generated by
analysis of samples, making data management a core
activity of biobanks.
Recent Advances
The importance of pre-analytical standards has been
attested by key features of the European Committee for
Standardization (CEN) Technical Specifications, which,
following the Vienna Agreement, became International
Organization for Standardization (ISO) standards this year.
The European biobanking research infrastructure BBMRI-
ERIC has mapped 60 million biosamples in Europe. A series
of the CEN Technical Specifications on sample pre-analytics
have been published to standardise sample quality, which is
essential for generating reproducible test results. These
standards are also relevant in the context of the European
Union Regulation BIn vitro Diagnostics and Medical
Devices^ since diagnostic developers have to provide data
on pre-analytical sample requirements to guarantee assay
performance [39].
Digital histological images are a new and important
resource provided by biobanks. Here, a national digital
pathology infrastructure has been established at Austrian
medical universities employing latest scanning technology
to generate a unique imaging data resource to drive
machine learning and imaging biomarker development
(Fig. 3). Developments in machine learning have created
an extensive interest in large-scale imaging data of tissues
that generate synergies between biobanks, digital pathol-
ogy and information and communication technology (ICT)
industry for driving innovation in imaging biomarkers.
Future Challenges
There is a need for large-scale and standardised annota-
tion of training data sets and to make results generated by
machine learning explicable. Developments in digital
pathology and imaging are converging to create a stimulat-
ing momentum for innovation in AI and imaging bio-
markers. The increasing role of accessing large data sets and
the need for international collaboration including data
Fig. 2. Framework for multi-modality molecular testing of biospecimens that may be used to identify molecular targets for
precision oncology in lung cancer patients. FFPE, formalin-fixed paraffin-embedded; FNA, fine-needle aspiration.
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exchange pose new challenges in privacy protection and
ethical and legal compliance.
Molecular Imaging and Omics
The Issues
Recent large-scale trials that target exploitable muta-
tions pharmacologically have yielded largely disappoint-
ing results. This can be explained in parts by the limited
number of effective targeted drugs, the small number of
cancers that exhibit single oncogene addictions and, thus,
the susceptibility to single-drug treatments. Furthermore,
targeting a comparatively large number of mutations
requires rationally designed combination therapies. Thus,
precision oncology based on genomics remains an elusive
goal [6, 39].
Recent Advances
Theranostics is an example of precision medicine. It
combines target identification and confirmation with
therapies that bind to the same target with high affinity
and specificity. Recent reports on targeting fibroblast-
activated protein (FAP), a highly relevant tumour
stroma target, suggest numerous potential theranostic
applications across many cancers [40] (Fig. 4). Other
examples for image-derived predictive biomarkers in-
clude assessments of hormone receptor status (estrogen
receptors, androgen receptors) [41, 42], protein expres-
sion (human epidermal growth factor receptor 2
(HER2neu)) and many more [43].
Future Challenges
n light of the significant differences between the results
of genomic testing obtained from tissue, liquid biopsies
and molecular imaging, a consensus should be developed
to integrate the results of these disparate yet complemen-
tary diagnostic modalities in a disease-specific manner
[44]. This requires new methodological approaches to-
wards the combination of multi-parametric image features
(aka Bradiomics^) and multi-omics data from tissue or
liquid biopsies so as to yield clinically relevant informa-
tion. Here, artificial intelligence–based approaches have
been proposed as one way to derive predictive biomarkers
for therapeutic responses in cancer [45, 46].
Digital Biomarkers and Patient Data Mining
The Issues
Information technology (IT) and companies have
transformed our digital footprints into an important
commodity. Collections of heterogeneous data from a
multitude of sources, such as social network posts and
biosensors, are increasingly used for health-related pre-
dictions. The challenge presented by the unstructured,
Fig. 3. Biobanks and machine learning/artificial intelligence (AI): a novel way of linking biosamples, images and disease
outcome.
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noisy and incomplete nature of these data is addressed by
a new generation of powerful, neural network–based
classification technologies (Fig. 5) [47].
Recent Advances
The term Bdigital biomarkers^ was coined to denote
objective, quantifiable physiological and behavioural data
collected and measured by means of portable, wearable or
implantable devices [48]. Digital biomarkers are data or data
extracts that can be obtained from all kinds of artefacts
related to an individual, and on which health-related
predictions can be grounded. Digital biomarkers can be
harvested from mobile appliances as well as raw textual and
other signals, through publicly available sources and
electronic health records (EHRs). Likewise, the potential of
big data analytics for healthcare, including digital bio-
markers, and prevention is well appreciated [49, 50].
Fig. 4. PET/CT maximum-intensity projections of patient with metastasised pancreatic cancer (a) and patient with breast
cancer (c). Maximum standardized uptake (SUVmax) of 68Ga-labelled FAPI in breast cancer lesions; Me = Metastasis. Note the
favourable biodistribution of the FAPI ligand for use as a theranostic compound with very high target and very low background
activity. Image taken from [40] with approval by publisher.
Fig. 5. The triangle between imaging, omics and networks
and clinical data.
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Future Challenges
The application of digital biomarkers in clinical decision
support systems requires a higher level of standardisation.
By nature, data in electronic health records are heteroge-
neous, and are primarily collected for human communication
and documentation, but not intended for automated decision
support or risk stratification. Therefore, the digital footprint
of EHR data is neither well-structured nor complete. Most of
EHRs are plain text, and structured information is collected
for purposes, such as billing, quality assurance and disease
reporting only.
Adequate secondary use of EHR data, according to the
FAIR (Findable, Accessible, Interoperable and Re-Usable)
data principles [51], is a challenge for natural language
processing (NLP) approaches [52], supported by domain
terminologies and ontologies [53–55]. Due to different
levels of complexity and missing contextual information,
distinct strategies are required to transform existing EHR
data for the use of data mining. Once the individual patient
data is formatted and prepared, it will be necessary to




Interactomics is a crossover discipline at the intersection
of bioinformatics and molecular biology that relates to the
studies of physical or functional interactions of proteins and
other molecules within a cell and the consequences of those
interactions. Networks provide a data-driven and simple but
integrative mathematical framework for the inference of
genotype-phenotype relationships that can handle large-scale
molecular data, which reflect complex molecular relation-
ships but may be governed by small quantitative differences
and may carry methodological biases.
Being a critical component of the genotype-phenotype-
function paradigm, networks provide a framework that most
directly connects molecular information such as sequence
variants to phenotypic traits [56]. However, a gap exists
between nucleotide resolution genome data and proteomics
data, which typically refer to changes of a protein as a whole
[57].
Recent Advances
The parallel quantification of proteomes from a series of
cancer cells recently established a connection between copy
number variation [58] or nucleotide variation [59] and
proteome changes at the protein interaction network level.
Concerted proteome changes can be linked to genetic
changes via data integration with networks using interac-
tome network models.
A second new development addressing the resolution gap
between proteomics and genomics involves deep mutational
scanning approaches [60]. Highly diverse genetic libraries,
e.g., representing all single-amino acid substations of a
protein of interest, are coupled to a phenotypic selection and
can be assessed through massive parallel sequencing.
Recently, a novel approach that couples deep scanning
mutagenise to protein interaction networks via a reverse
yeast two-hybrid technique was introduced [61].
Future Challenges
Today, amino acid resolution protein interaction profiles
can be recorded on an interactome scale. Interaction
perturbation profiles could potentially serve as a sequence-
based functional biomarker with the advantage to include
rare and newly diagnosed gene variants. Nonetheless, efforts
must focus on human interactome mapping that also
addresses condition- and tissue-specific network informa-
tion. Here, computational methods will play a crucial role in
transforming current data generation approaches into diag-
nostic or clinically applicable information.
Track 2: Biomarker and Treatment
Biomarkers can serve as surrogates for the presence of
respective treatment-relevant target structures when selecting
and guiding targeted therapies in cancer patients (Table 3).
The derivation of biomarkers is considered as a cost-
intensive process that helps generate very useful and cost-
effective databases for local and remote teams working in
the field of drug discovery. Therefore, standardisation of
biospecimen and biomarker sourcing procedures is a key to
an efficient biomarker derivation and validation and subse-
quent data analysis [7].
The Needs for Standardised Pre-analytics in
Biobanking
The Issues According to Freedman and Inglese, the share
of pre-clinical, biological research studies that failed to be
reproduced ranges from 68 to 89 % [62]. It is estimated that
in the USA alone, US$28 billion is wasted annually due to
irreproducible results, with over a third of it being caused by
poor reference materials and biological reagents [63]. Thus,
it is not surprising that more than half of the papers reporting
Table 3. Track 2: progress indicators for biomarkers and treatment
planning
Feature 2016 2018
Biobanks and evidence creation ↔ ↔
Standardisation of pre-analytics biobanks ↔ ↔
GMP as roadblock to translational research ↗ ↗
Tracers for the immune system ↔ ↗
Clinical immunotherapy ↔ ↗
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biomarker discoveries do not contain any information about
the biospecimens used, although some of them were
published in interdisciplinary top journals [64].
Recent Advances To minimise pre-analytical variability in
research biobanking, large biobank consortia, such as the
European Research Infrastructure Consortium BBMRI-
ERIC and its national nodes, foster the implementation of
technical specifications (TSs) during the pre-examination
phase [65]. Given that governance aspects, ethical require-
ments and sample access remain largely undervalued, an
international biobank–specific quality management standard
(ISO 20387—BGeneral requirements for Biobanking^) was
recently released. TSs on the pre-examination process
require the validation of the whole process, which starts
with the collection of the sample and ends with the
interpretation of the analytical results.
Future Challenges Despite increasing evidence of a higher
pre-analytical quality positively affecting research reproduc-
ibility and scientific progress, the community must engage in
building and adhering to evidence-based international
protocols [66–68].
Standardised Pre-analytics in Biomarker
Research
The Issues Profiles of biomolecules can change signifi-
cantly during pre-analytical workflows. Previous studies
have demonstrated that changes in RNA expression or
protein and phosphoprotein amounts can occur at every
stage of the sample processing workflow starting with the
collection and extending to the archival of the processed
samples [69–72]. This can lead to unreliable results or
misinterpretation of the bioanalytical profiles generated in
the pre-analytical phase. Of note, diagnostic errors contrib-
ute to up to 10 % of all patient deaths and 17 % of adverse
events. The pre-analytical workflows are the largest contrib-
utors to the error rate and account for 46–68 % of clinical
laboratory errors [73].
Recent Advances A new EU In Vitro Diagnostic Device
Regulation 2017/746 [74] (IVDR) was put into effect in
May 2017, thereby replacing the old IVD Directive 98/79/
EC (Official Journal of the European Union, Legislation,
Vol. 60, May 5, 2017). A key modification in the new IVDR
is the introduction of sampling requirements for the
analytical performance of an in vitro diagnostic test.
The new Horizon 2020 SPIDA4P consortium project
(2017–2020) intends to broaden the portfolio of CEN and
ISO standards for pre-analytical workflows by generating
and implementing finally a comprehensive portfolio of 22
pan-European pre-analytical CEN/technical specifications
and ISO/international standards, addressing important pre-
analytical workflows such as those applied to personalised
medicine (www.spidia.eu).
Future Challenges Additional new pre-analytical
workflow technologies and IVD products on specimen and
sample collection, stabilisation, transport, storage and pro-
cessing are still required for various new applications, e.g.,
for CTC characterisation, circulating nucleic acid analysis
from non-invasive human samples, next-generation sequenc-
ing (NGS) and metabolites in human samples. In addition to
supporting technology advances, the implementation of the
new IVDR and CEN and ISO standards for pre-analytical
workflows will remain a major task for the next years.
Corresponding external quality assurance (EQA) schemes
will be developed and implemented as well, aiming to
survey the resulting quality of samples and diagnostic
practice.
Role of Mass Spectrometry in Quality Analysis
and Analytics
The Issues In mass spectroscopy, determinants that may
compromise sample quality must be minimised [75] in order
to obtain samples that assure reproducible and credible
results. Despite great efforts to reduce the error rates of pre-
analytical stage of sample handling, pre-analytical errors still
account for up to 70 % of all problems occurring in
laboratory diagnostics [76–78] and include hemolysis,
coagulation (clotting), inadequate filling volume of the
blood collection vial and insufficient information on the
blood collection rube or the sample vial [79–82].
Recent Advances For example, the quality of blood
samples can be affected in multiple ways [83]. It was found
that 4–19 % of metabolites were upregulated by mishandling
of the samples and 8–12 % of single metabolites were
downregulated compared to control samples. Another study
from the same group demonstrated significant changes of
metabolites when the incubation time of blood samples was
prolonged [81]. In particular, amino acids and nucleobases
were demonstrated to be sensitive for these affections.
Future Challenges Ongoing studies accentuate the impor-
tance of high-quality biospecimens in the biobanks, as well
as a need for identification of more biomarkers of sample
quality.
Translational Immunology: Tackling Barriers in
Science and Bureaucracy
The Issues Immunotherapy has become a mainstay of
oncological treatment. The ability to stimulate Fc receptor
(FcR)–bearing effector cells, which results in lysis of target
cells (antibody-dependent cellular cytotoxicity (ADCC)), is
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central for the immunotherapeutic activity of monoclonal
antitumour antibodies, in particular in hematological malig-
nancies. In humans, natural killer (NK) cells constitute the
major cell population that mediates this important antibody
function [84]. However, the success of rituximab and other
so far available antitumour antibodies is limited with regard
to efficacy and due to the lack of compounds for many other
cancer entities.
A major drawback of strategies to mobilise T cells against
cancer is that they cause partially severe side effects. In case
of checkpoint blocking antibodies, these arise from the
general, undirected activation of the T cell system. In case of
presently available bispecific antibodies (bsAbs) and chime-
ric antigen receptor (CAR) T cells, side effects are largely
due to the fact that the employed target antigens are
expressed not only on malignant but also on healthy cells,
such as B cells in case of CD19. A second major drawback
is, as mentioned above, that available bsAbs and CAR T
cells are far less successful in solid tumours than hemato-
poietic malignancies.
Recent Advances Hofmann and collaborators [85] recently
developed an Fc-optimised monoclonal antibody targeting
the surface antigen FLT3 (CD135), which is expressed on
leukemic cells in nearly all patients with acute myeloid
leukaemia (AML), for which no immunotherapy is available
to date. An alternative approach to improve the therapeutic
efficacy of antitumour antibodies is to develop strategies,
which allow for antibody-mediated stimulation of T cells
with their—compared to NK cells—profoundly higher
effector potential [86].
A recent publication confirmed the relevance of targeting
vascular antigens for cancer treatment [87]. Accordingly, a
bsAb directed to prostate-specific membrane antigen
(PSMA) was developed, which is expressed on prostate
carcinoma cells as well as on tumour-associated vasculature
of numerous other cancers. This PSMAxCD3 bsAb termed
CC-1 was constructed in a novel, whole IgG-based (IgGsc)
format with increased serum half-life. CC-1 contains a
proprietary PSMA antibody, which displays additional
unique reactivity with squamous cell carcinoma (SCC) of
the lung, allowing for the desired dual targeting of both
tumour cells and neovasculature.
Future Challenges A plethora of compounds with pre-
clinically substantiated antitumour efficacy awaits clinical
evaluation and holds great promise to benefit cancer
patients. At present, the biggest challenge is the steadily
increasing regulatory burden with regard to both require-
ments regarding production (good manufacturing practice,
GMP) and lately also for clinical evaluation (good clinical
practice, GCP). Together, they dramatically extend the time
from conceptualisation of a drug to its clinical evaluation,
but notably, the first also almost completely bars academic
institutions from drug development [88]. It is worth to
consider whether and how in the particular case of cancer
patients with a life-threatening disease, who failed to
respond to established/available therapy, novel compounds
with pre-clinically proven efficacy can be made more rapidly
available. In addition, the costs of drug development and
ultimately treatment costs, which are becoming a tremen-
dous socio-economic challenge in the future, must become a
focus of our attention.
Tracers to Target the Immune System
The Issues Immune-modulating therapies not only target
the cancer cells but also modulate the cancer-promoting or
cancer-inhibiting properties of the complex multi-cellular
tumour microenvironment (TME) [89–91]. There are still a
large number of patients that do not respond to the chosen
immune-modulating therapy. Therefore, understanding the
dynamic changes in the TME, in particular those involving
the immune system, may help advance the development of
new strategies for cancer diagnosis, treatment and assess-
ment of therapeutic response.
Thus, there is a need for translational and validated
biomarkers for the prediction and monitoring of responders
to immune system–modulating drugs and categorising
responsive tumours early after therapy initiation in a non-
invasive manner. Unfortunately, an increase of infiltrating
immune cells that have an increased glucose metabolism
compared with peripheral non-immune cells pretends a
transient worsening (pseudo-progression) in [18F]FDG PET
[92].
Recent Advances Currently, one of the most interesting
targets for therapy and imaging is the immune checkpoint
protein, PD-1 ligand (PD-L1). PD-L1 is over-expressed by a
variety of tumour cells, induced as an adaptive mechanism
in response to tumour-infiltrating cytotoxic T cells [93].
Increased PD-L1 expression in cancer cells as well as in
TME promotes immune evasion of tumour cells via binding
to PD-1 expressed by the active immune infiltrates [94]. A
number of studies have demonstrated anticancer activity of
PD-L1–targeting antibodies [95]. For in vivo detection of
PD-L1, clinical advances have been made using
rad iolabel led ant ibodies such as atezol izumab
(ClinicalTrials.gov identifiers NCT02453984 and
NCT02478099) [96].
In addition, other key mediators in immune cell
activation/inactivation and various types of cells involved
in immune regulation offer additional potential targets for
imaging response to immunotherapy [97]. Novel, potential
targets and targeting agents are currently under investigation
[98]. A list of immunotargets and targeting concepts is
shown in Table 4.
Future Challenges Major challenges on the way to
imaging biomarkers in immunotherapies include
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translational gaps as a result of lack of or inadequate in vitro
and animal models that allow assessing novel radiotracers;
the time for clinical validation of novel, imaginable
biomarkers; repetitive exposure of patients to ionising
radiation; and the cost for tracer development and clinical
studies.
Targeting the Immune System: a Clinical
Perspective
The Issues Tumour cells express or induce molecules,
which block cytotoxic tumour ablative immune cells, such
as cytotoxic T cells [114]. Vice versa, a rational and efficient
tumour immunotherapy is based on the identification and
subsequent blockage of those pathways by immune check-
point inhibitors.
Recent Advances One of the best predictive markers for
PD-1 blockade is microsatellite instability (MSI) [115]. It is
anticipated that the MSI-associated increase in mutations
resulting in an increased rate of neo-antigens is substantial
for the observed therapeutic effect in those patients.
In 2017, the FDA approved PD-L1 inhibitors for
unresectable or therapy-resistant metastatic MSI-positive
solid cancer. An association of mutational burden and a
therapeutic effect of a checkpoint blocker have also been
demonstrated for the CTLA-4 antibody ipilimumab [116].
The PD-L1 inhibitor pembrolizumab revealed a benefit for
patients with metastatic non-small cell lung cancer (NSCLC)
compared to platinum-based chemotherapy with an overall
response rate of 45 % versus 28 %, respectively [117].
PD-L1 or PD-1 blockade have also been highly successful in
phase II studies in Morbus Hodgkin, leading to an overall
response rate of more than 60 %. In this disease, the expression
of the receptors is increased due to genetic aberrations, such as
copy gain or amplification [118]. Currently, the EMA approval
of checkpoint inhibitor includes MSI cancer, NSCLC, Hodgkin
lymphoma, melanoma, head and neck cancer, urothelial cancer,
kidney cancer and Merkel cell cancer.
Future Challenges The success of these initial studies did
not only promote the development of antibodies against
other checkpoint molecules, such as LAG3 or TIM3, but
also combination therapy with other agents. Despite first
publications showing anti-PD-1 antibody to be effective also
in microsatellite-stable cancers in light of combination
therapies [99, 119], future studies have to provide additional
evidence of such combined approaches.
Oncolytic viruses have been developed for most of the
viral families [120], and the combination of an FDA-
approved oncolytic herpes virus with an anti-PD-L1 anti-
body led to a clinical response of around 60 % in stage III
and stage IV melanoma. The effect was associated with a
high influx of cytotoxic T cells and an increase of PD-1
expression in tumour tissue. However, proof of evidence is
required to implement these approaches into the clinic.
Track 3: Evidence and Ethics
Until recently, drug development followed a clear path, i.e.,
from in vitro pharmacodynamic studies and experiments in
animals to first-in-men studies in healthy volunteers as well
as in patients. If successful, this process would be followed
by approval through regulators and, finally, reimbursement
negotiations with payers. While this one-way pathway
employing the interaction between stakeholders at
predefined time points clearly still does exist, recent
Table 4.. Targets and nuclear targeting concepts and agents that are currently under investigation for monitoring immunotherapies (adapted from [99] and
expanded)
Target Cell type and function Proposed tracers





Deoxycytidine kinase Immune cell proliferation L-[18F]FAC [101, 102]
Deoxyguanosine kinase T lymphocyte activation [18F]AraG [103]








CD11b/MHC-II Neutrophils [18F]/[64Cu]anti-CD11b/MHC-II-Ab [62]
Transgenic T
cell receptor (TCR)
Transgenic T cells [89Zr]/[64Cu]anti-TCR-Ab [108, 109]






FR-β Macrophages (TAMs) [18F]AzaFol [112, 113]
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approaches aim at early and more flexible interactions of
involved players.
Medical ethics does play a key role during these stages
(Table 5), perhaps best defined in the sixth paragraph of the
Declaration of Helsinki, the key document for ethics in
medical research: BThe primary purpose of medical research
involving human subjects is to understand the causes,
development and effects of diseases and improve preventive,
diagnostic and therapeutic interventions (methods, proce-
dures and treatments). Even the best proven interventions
must be evaluated continually through research for their
safety, effectiveness, efficiency, accessibility and quality.^
(https://www.wma.net/policies-post/wma-declaration-of-hel-
sinki-ethical-principles-for-medical-research-involving-hu-
man-subjects/). This depicts well the inseparable binding
between ethics (Bwhat can I do?^) and evidence (Bwhat do I
know?^ and Bwhat do I want to know?^) but also
encourages the community as such to continuously chal-
lenge their Bstandard of care^.
Cost-Effectiveness Aspects of Biomarker
Development
The Issues Providing value for money, identifying the best
course of action based on the available evidence and optimal
allocation of resources from the given budget are the central
concepts of cost-effectiveness analyses (CEAs). CEAs
evaluate the difference in costs relative to the difference in
effects between competing alternative activities. They are
commonly used decision-making support tools in the context
of health economics and health technology assessments
(HTAs) to identify the value of new health technologies.
The top ten most common medications in the USA help
between 4 and 25 % of patients [121]. Spending on cancer
drugs has increased faster than spending in most other areas
of healthcare, because of rising prices and increased use.
Diminishing rate of return in terms of the benefit gain
associated with the increased costs is another concern [122].
Recent Advances Biomarkers may present multi-faceted
values: clinical value is achieved by directing effective
targeted therapy, informative value is achieved by reduced
uncertainty about treatment benefits, financial value is
achieved by reducing costs spent on ineffective care and
economic value is achieved by providing greater benefits for
the amount paid than the benefits of potential alternative use
of the same resources (the so-called Bopportunity cost^)
[123].
Traditional HTAs and CEAs focus on population average
results to support population-level reimbursement decisions
and generally ignore patient variations or broader value
aspects leading to potentially ineffective and futile use of
healthcare resources. Establishing the different value aspects
of biomarker tests requires the application of a broader value
framework and the explicit consideration of patient hetero-
geneity [124].
Future Challenges Conducting the value evaluation of
biomarker tests usually require more data, time and
analytical resources than traditional pharmacoeconomic
evaluations. Although procedurally challenging, early inclu-
sion of HTA in the development process can promote cost-
effectiveness of the developed test. Since relevant evidence
may not be available at the time of readiness for marketing,
new reimbursement policy models (e.g., c\overage with
evidence development) are also required to allow the earliest
possible availability for patient care [125].
Precision Medicine: Mapping the Ethical
Challenges
The Issues One of the central technical challenges of any
biomarker-focused precision medicine approach is success-
ful translation from bench to bedside and from lab to
lifeworld [126]. On the technical side, and as evidenced at
the meeting, significant work is currently being done to
ensure advanced biomarkers are developed that are clinically
actionable and help improve understanding of disease
progression and individual patient care. However, to reach
this goal, technology and clinical development need to
consider various important ethical and social issues.
Recent Advances A knowledge gap with doctors regarding
the multiplexed facets of biomarker development and use
has been identified [127]. However, studies on how this gap
plays out in clinical decision-making and how it can be
managed or even avoided are missing. Likewise, more
information on patients’ understanding of advanced bio-
marker approaches, their expectations, attitudes and values
as well as their concerns need to be collected, to assist future
patient care and policymaking. From a philosophical
perspective, understandings and illness taxonomies are
Table 5. Track 3: progress indicators for ethics and evidence aspects of biomarker development
Feature 2016 2018
Biomarker as a decision tool for regulators like EMA and FDA ↔ ↗
Biomarker considered by payers ↔ ↔
Biomarker reflected in scientific guidelines ↗ ↗
Biomarker impact on ethics committee approval ↗ ↗
Addressing ethical issues in personalised medicine ↔ ↔
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currently shifting [128]. On the sociological side, important
discussions focus on whether precision medicine contributes
to the medicalisation of pre-disease states and/or social
trends, and whether precision medicine could potentially be
a poor choice while a low-tech public health approach is
perhaps more appropriate and cost-effective.
Future Challenges Studies mapping the specific ethical
and social issues of advanced biomarker approaches,
including the studied disease entities, are required.
Value of Diagnostics to Health Systems
The Issues Research and development need to be mindful
of the ultimate aim of healthcare technologies. The last
hurdle for these technologies to access the market is
reimbursement. Such decisions are often preceded by an
HTA, which is mandatory in many countries for pharma-
ceuticals and is increasingly being undertaken for medical
devices and other diagnostic technologies and activities in
Europe.
Recent Advances Clinical value is measured in population
health, often using generic metrics that allow cross-condition
comparisons. In the UK and many other European countries,
the measure used is the quality-adjusted life year (QALY).
Because any additional costs imposed on the healthcare
system means that these resources cannot be used in other
ways, some health is lost or foregone (aka Bhealth
opportunity costs^).
With regard to diagnostic tests, HTA often considers not
only which test should be used in clinical practice but also
how the test should be used, that is, what is the best way to
proceed, clinically, using the information it provides [124,
129–132].
Future Challenges The mechanism of value accrual for
diagnostic technologies differs to that of pharmaceuticals.
Tests identify the level or magnitude of factors that
determine or explain health outcomes. In this regard, tests
identify patients who are expected to benefit most from
distinct regimens of healthcare. It is only by tailoring
treatment decisions to patients, that is the expected (net)
health of the overall population improves and value is
generated. This means that, ultimately, the value of the test
is bound by the value of available treatments and condi-
tioned by other technologies in the diagnostic pathway (e.g.,
combinations of tests or sequences of tests). Value also
critically depends on prevalence, on the costs or adverse
events of the technology and on the level of misclassification
(false positives and false negatives).
Paradigm of Predictive Medicine and Ethical
Challenges
The Issues The possible role of genetic information in a
future healthcare system, in which Bsystems medicine^
approaches (Fig. 6) are applied, is currently intensely debated
[133–136]. But, the question of whether the importance and
role of genetics will either increase or decrease in such a
healthcare system remains unanswered.
Recent Advances Systems medicine reconciles heteroge-
neous approaches, using not only modelling methods of
systems biology to obtain information about the aetiology of
complex diseases but also integrating big amounts of data
from various sources (omics data, data from imaging
methods, treatment data, etc.) as well [137–140]. By
committing itself to the paradigm of predictive medicine,
ethical challenges remain highly virulent in the approach of
systems medicine. Depending on a specific disease, systems
medicine could contribute to a boost of genetic prediction
and could strengthen the role of non-genetic predictors [133,
139, 141, 142].
Future Challenges The question of how patients and
doctors can deal with probabilities and risks must be
addressed and communicated across all stakeholders. Here,
the question of a future relevance of algorithms and scores
for the decision-making process within the context of a
medical treatment is crucial. The problem of so-called
Bhealth-related personal responsibility^ remains potentially
as relevant for systems medicine as it is for the approaches
of precision medicine and individualised medicine. Chal-
lenges regarding the clinical processing of incidental or
secondary findings could arise from the translation of
systems medicine into clinical practice [138].
Fig. 6. Systems medicine can be understood as a hetero-
geneous set of methods and approaches connected by an
emphasis on information technologies.
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Round Table Discussion: What Is
Needed to Breed the Next Generation
of Experts in Molecular Diagnostics?
It is obvious that current educational and training schemes
that support the in-depth expertise of individual and
autonomous fields of research are no longer appropriate to
embrace the multi-disciplinary approach to (cancer) patient
management [143]. This was obvious from a spirited debate
as well. The panelists together with the audience then carved
out requirements for the education of the next generation of
biomarker experts, or Bexperts in molecular diagnostics^.
In view of the existing gap between clinical and basic
research expertise, which is a major bottleneck to generate
experts in molecular diagnostics, it was reiterated that here
are currently too few combined training pathways that
provide training in genetics, inherited genetic disorders,
oncology and molecular imaging. Moreover, limiting the
preclinical competence to genomics ignores the critically
important role of signaling networks in cancer and other
diseases. Efforts should be made to introduce clinicians to
animal models, drug development and biology of disease (in
addition to imaging). Such improved mechanistic insights
could lead to accelerated translation into clinical benefits.
There is a need for compact training curricula as economic
pressure including large debt volumes force trainees to join
the work force quickly. It was suggested that there was an
inverse relationship between general and speciality training.
The sophistication and depth of knowledge and skills to
practice molecular diagnostics would require 3–4 years of
training and less general training. An alternative approach
would be the expansion of postgraduate fellowships for
physicians in molecular diagnostics. This should be
synchronised with passion and enthusiasm among the
faculty in order to most effectively spread the energy and
excitement about molecular methodologies to trainees and
colleagues.
Panelists and attendees appreciated the significant differ-
ences in career development opportunities between the USA
and Europe (e.g., the nuclear medicine training duration is
5 years in Europe vs. 3 years in the USA). Nonetheless,
research fellowship like opportunities is available in both
continents that could be used to strengthen the basic science
component. The audience did not quite agree on whether
creating more structured learning opportunities would
enhance physicians’ interest in pursuing research. However,
it was conceded that clinicians were often poorly educated
and informed about omics platforms, such as proteomics and
metabolomics, and that such opportunities should be
supported and sponsored by academic institutions, founda-
tions and government agencies.
Conclusions and Outlook
Biomarker discovery and validation should become part of a
Bbig science approach^ [7], which involves multiple
stakeholders from both academia and industry and experts
in molecular pathology, genetics, molecular imaging, com-
puter science, statistics, epidemiology, regulations and
healthcare economics. However, such an approach mandates
to overcome obstacles that reside within the existing culture
of research organisations and ecosystems. Likewise, oppor-
tunities and abilities to communicate across stakeholders
must be expanded, and deficiencies in (large sample)
analytical technologies must be addressed.
The 2nd Donau Symposium provided an important forum
for individuals involved in biomarker research with an
empathy for cross-speciality engagement, such as in the
validation of liquid biopsies and circulating tumour cells,
where traditional single-feature biomarkers will be replaced
by next-generation biomarker (e.g., derived from computa-
tional models). Cross-speciality engagement will yield also
attention to the role of quantitative biomarkers, which is
expected to grow [2]. When combining quantitative, visual
and non-imaging biomarkers, standardised sourcing proce-
dures as well as harmonisation measures will become
essential for merging relevant information and building
models and prediction algorithms that help advance patient
management strategies.
In the future, the concept of precision medicine can be
supported only if traditional ways of sourcing biomarker
information are combined with environmental/lifestyle fac-
tors [144] and modern concepts of molecular imaging. While
the 1st Donau Symposium in 2016 intended to blend, the
2nd in 2018 aimed to converge. We are now looking
forward to our 3rd Symposium in 2020 to making it real!
Acknowledgments. Open access funding provided by Medical University of
Vienna. We wish to thank all participants for their active contribution at the
2nd Donau Symposium and for the lively discussions. In particular, we like
to acknowledge contributions from Claudia A. Castro Jaramillo, Stefanie D.
Krämer and all faculty/moderators who did not engage in this white paper.
Further, we like to acknowledge the generous support of the symposium
sponsors: ABX advanced biochemical compounds, Austrian Institute of
Technology (AIT) GmbH, BSM Diagnostica, DSD Pharma GmbH,
Elimpex-Medizintechnik GmbH, Elysia-Raytest, Eurisotop, GE Austria,
Hermes Medical Solutions, HVD Life Science Vertriebs GmbH, Iason
GmbH, Ipsen Pharma GmbH, ITM Isotopen Technologien München AG,
Mediso GmbH, Philips Austria GmbH, Philogen, Qiagen, Rotem GmbH,
Rotop, Seibersdorf Labor GmbH, Siemens Healthcare Diagnostics GmbH,
Sofie Biosciences Acquired Zevacor and THP Medical Products Vertriebs
GmbH.
Funding Information. The SPIDIA project has received funding under the
Seventh Research Framework Programme of the European Union, FP7-
HEALTH-2007-1.2.5, under grant agreement no. 222916. The SPIDIA4P
project receives funding from the European Union’s Horizon 2020 research
and innovation programme under grant agreement no. 733112.
Compliance with Ethical Standards
Conflict of Interest
RJH holds stock in Telix Pharmaceuticals on behalf of the Peter MacCallum
Cancer Centre.
TB is a co-founder of cmi-experts GmbH. TB and MH are co-founders of
Dedicaid GmbH.
Lim M.S. et al.: Advancing Biomarker Development Through Convergent Engagement
Open Access This article is distributed under the terms of the Creative
Commons At t r i bu t i on 4 .0 In t e rna t i ona l L i c en se (h t t p : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropri-
ate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Ballman KV (2015) Biomarker: predictive or prognostic? J Clin
Oncol 33:3968–3971
2. Lammertsma AA (2017) Forward to the past: the case for quantitative
PET imaging. J Nucl Med 58(7):1019–1024
3. Bailey DL (2014) Thirty years from now: future physics contributions
in nuclear medicine. EJNMMI Physics 1:4
4. Cancer Genome Atlas Research Network, Weinstein JN, Collisson
EA, Mills GB et al (2013) The Cancer Genome Atlas Pan-Cancer
analysis project. Nat Genet 45:1113–1120
5. Hacker M, Hoermann G, Kenner L (2018) Molecular imaging and
molecular diagnostics: two sides of the same coin? Eur J Nucl Med
Mol Imaging 45:1645–1648
6. Lee JK, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, Cho HJ, Elliott O,
Chu T, Choi SW, Rosenbloom DIS, Lee IH, Shin YJ, Kang HJ, Kim
D, Kim SY, Sim MH, Kim J, Lee T, Seo YJ, Shin H, Lee M, Kim SH,
Kwon YJ, Oh JW, Song M, Kim M, Kong DS, Choi JW, Seol HJ, Lee
JI, Kim ST, Park JO, Kim KM, Song SY, Lee JW, Kim HC, Lee JE,
Choi MG, Seo SW, Shim YM, Zo JI, Jeong BC, Yoon Y, Ryu GH,
Kim NKD, Bae JS, Park WY, Lee J, Verhaak RGW, Iavarone A, Lee
J, Rabadan R, Nam DH (2018) Pharmacogenomic landscape of
patient-derived tumor cells informs precision oncology therapy. Nat
Genet 50:1399–1411
7. Poste G (2011) Bring on the biomarkers. Nature 469:156–157
8. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J,
Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz
A, McCombie WR, Hicks J, Wigler M (2011) Tumour evolution
inferred by single-cell sequencing. Nature 472:90–94
9. Cleary AS, Leonard TL, Gestl SA, Gunther EJ (2014) Tumour cell
heterogeneity maintained by cooperating subclones in Wnt-driven
mammary cancers. Nature 508:113–117
10. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F,
Polyak K (2014) Non-cell-autonomous driving of tumour growth
supports sub-clonal heterogeneity. Nature 514:54–58
11. Koren S, Bentires-Alj M (2015) Breast tumor heterogeneity: source of
fitness, hurdle for therapy. Mol Cell 60:537–546
12. Alix-Panabières C, Pantel K (2016) Clinical applications of circulating
tumor cells and circulating tumor DNA as liquid biopsy. Cancer
Discov 6:479–491
13. Babayan A, Pantel K (2018) Advances in liquid biopsy approaches for
early detection and monitoring of cancer. Genome Med 10:21
14. Pantel K, Alix-Panabières C (2010) Circulating tumour cells in cancer
patients: challenges and perspectives. Trends Mol Med 16:398–406
15. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C,
JavedAA,WongF,MattoxA,HrubanRH,WolfgangCL,GogginsMG,Dal
Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J,
SillimanN, PopoliM,Vogelstein JT, Browne JD, Schoen RE, BrandRE, Tie
J, Gibbs P,WongHL,MansfieldAS, Jen J, Hanash SM, FalconiM,Allen PJ,
Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B,
Lennon AM, Papadopoulos N (2018) Detection and localization of surgically
resectable cancers with a multi-analyte blood test. Science 359:926–930
16. Heitzer E, Haque IS, Roberts CE et al (2019) Current and future
perspectives of liquid biopsies in genomics-driven oncology. Nat Rev
Genet 20:71–88
17. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben
JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA,
Hortobagyi GN, Terstappen LWMM (2005) Circulating tumor cells: a
novel prognostic factor for newly diagnosed metastatic breast cancer. J
Clin Oncol 23:1420–1430
18. Cohen SJ, Punt CJ, Iannotti N et al (2008) Relationship of circulating
tumor cells to tumor response, progression-free survival, and overall
survival in patients with metastatic colorectal cancer. J Clin Oncol
26:3213–3221
19. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing
H, Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D (2008)
Circulating tumor cells predict survival benefit from treatment in
metastatic castration-resistant prostate cancer. Clin Cancer Res
14:6302–6309
20. Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J,
Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Schem C, von
Minckwitz G, Untch M, Pantel K (2017) Prognostic impact of
circulating tumor cells for breast cancer patients treated in the
neoadjuvant BGeparquattro^ trial. Clin Cancer Res 23:5384–5393
21. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A,
Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba
S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V,
Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A,
Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, di
Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A
(2015) Clonal evolution and resistance to EGFR blockade in the blood
of colorectal cancer patients. Nat Med 21:827
22. Tie J, Wang Y, Tomasetti C, Li L et al (2016) Circulating tumor DNA
analysis detects minimal residual disease and predicts recurrence in
patients with stage II colon cancer. Sci Transl Med 8:346ra92
23. Abbosh C, Birkbak NJ, Wilson GA et al (2017) Phylogenetic ctDNA
analysis depicts early-stage lung cancer evolution. Nature 545:446–
451
24. Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-
Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B,
Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M,
Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S,
Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman
A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS,
TOPARP-A investigators (2017) Circulating cell-free DNA to guide
prostate cancer treatment with PARP inhibition. Cancer Discov
7:1006–1017
25. Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H
(2015) Aberrant plasma levels of circulating miR-16, miR-107, miR-
130a and miR-146a are associated with lymph node metastasis and
receptor status of breast cancer patients. Oncotarget 6:13387–13401
26. Meng X, Müller V, Milde-Langosch K et al (2016) Circulating cell-
free miR-373, miR-200a, miR-200b and miR-200c in patients with
epithelial ovarian cancer. Adv Exp Med Biol 924:3–8
27. Al-Qatati A, Akrong C, Stevic I et al (2017) Plasma microRNA
signature is associated with risk stratification in prostate cancer
patients. Int J Cancer 141:1231–1239
28. Anfossi S, Babayan A, Pantel K, Calin GA (2018) Clinical utility of
circulating non-coding RNAs—an update. Nat Rev Clin Oncol
15:541–563
29. Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR,
Emond MJ, Loeb LA, Swisher EM, Risques RA (2016) Ultra-deep
sequencing detects ovarian cancer cells in peritoneal fluid and reveals
somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci
U S A 113:6005–6010
30. Bardelli A, Pantel K (2017) Liquid biopsies, what we do not know
(yet). Cancer Cell 31:172–179
31. Bednarz-Knoll N, Alix-Panabières C, Pantel K (2012) Plasticity of
disseminating cancer cells in patients with epithelial malignancies.
Cancer Metastasis Rev 31:673–687
32. de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA
et al (2016) Targeted next generation sequencing as a reliable
diagnostic assay for the detection of somatic mutations in tumours
using minimal DNA amounts from formalin fixed paraffin embedded
material. PLoS One 11:e0149405
33. Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC,
Seibel NL, Parsons DW, Cho YJ, Janeway K, on behalf of the
Pediatric MATCH Target and Agent Prioritization Committee (2017)
Target and agent prioritization for the Children’s Oncology Group-
National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst
109. https://doi.org/10.1093/jnci/djw274
34. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R,
Jerin J, Young J, Byars L, Nutt R (2000) A combined PET/CT
scanner for clinical oncology. J Nucl Med 41:1369–1379
35. Mannheim JG, Schmid AM, Schwenck J, Katiyar P, Herfert K,
Pichler BJ, Disselhorst JA (2018) PET/MRI hybrid systems. Semin
Nucl Med 48:332–347
36. Bailey DL, Pichler BJ, Guckel B et al (2018) Combined PET/MRI: global
warming—summary report of the 6th international workshop on PET/MRI,
March 27-29, 2017, Tubingen, Germany. Mol Imaging Biol 20:4–20
Lim M.S. et al.: Advancing Biomarker Development Through Convergent Engagement
37. Bailey DL, Pichler BJ, Guckel B et al (2016) Combined PET/MRI:
from status quo to status go. Summary report of the fifth international
workshop on PET/MR imaging; February 15-19, 2016; Tubingen,
Germany. Mol Imaging Biol 18:637–650
38. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou
K, Pfannenberg C, la Fougère C (2017) Comparison of 68Ga-
labelled PSMA-11 and 11C-choline in the detection of prostate
cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging
44:92–101
39. Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS,
Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe
E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch
N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer
ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L,
Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R,
Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-
Furga G (2017) Image-based ex-vivo drug screening for patients
with aggressive haematological malignancies: interim results from
a single-arm, open-label, pilot study. Lancet Haematol 4:e595–
e606
40. Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jäger D, Giesel
F, Kratochwil C, Barthe P, Roumestand C, Haberkorn U (2018) A
tumor-imaging method targeting cancer-associated fibroblasts. J Nucl
Med 59:1423–1429
41. Schuster DM, Nanni C, Fanti S (2016) PET tracers beyond FDG in
prostate cancer. Semin Nucl Med 46:507–521
42. van Kruchten M, de Vries EGE, Brown M, de Vries EFJ, Glaudemans
AWJM, Dierckx RAJO, Schröder CP, Hospers GAP (2013) PET
imaging of oestrogen receptors in patients with breast cancer. Lancet
Oncol 14:e465–e475
43. Gaykema SB, Schröder CP, Vitfell-Rasmussen J et al (2014) 89Zr-
trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the
HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
Clin Cancer Res 20:3945–3954
44. Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien
AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen
RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD,
Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL (2018)
Clinical implications of plasma-based genotyping with the delivery of
personalized therapy in metastatic non-small cell lung cancer. JAMA
Oncol 5:173. https://doi.org/10.1001/jamaoncol.2018.4305
45. Schmitz J, Schwab J, Schwenck J, Chen Q, Quintanilla-Martinez L,
Hahn M, Wietek B, Schwenzer N, Staebler A, Kohlhofer U, Aina OH,
Hubbard NE, Reischl G, Borowsky AD, Brucker S, Nikolaou K, la
Fougère C, Cardiff RD, Pichler BJ, Schmid AM (2016) Decoding
intratumoral heterogeneity of breast cancer by multiparametric in vivo
imaging: a translational study. Cancer Res 76:5512–5522
46. Katiyar P, Divine MR, Kohlhofer U, Quintanilla-Martinez L,
Schölkopf B, Pichler BJ, Disselhorst JA (2017) Spectral clustering
predicts tumor tissue heterogeneity using dynamic 18F-FDG PET: a
complement to the standard compartmental modeling approach. J
Nucl Med 58:651–657
47. Purwar A, Singh SK (2015) Hybrid prediction model with missing
value imputation for medical data. Expert Syst Appl 42:5621–5631
48. Dorsey ER (2018) Digital biomarkers. https://www.karger.com/Jour-
nal/Home/271954. Journal, last accessed May 27, 2018
49. Sun J, Reddy CK (2013, 2013) Big data analytics for healthcare.
Tutorial. Proc. of the 19th ACM SIGKDD international conference on
Knowledge discovery and data mining. ACM:1525–1525 Slides:
https://de.slideshare.net/ChandanReddy4/big-data-analytics-for-
healthcare. Accessed 17 April 2019
50. Constine J (2017) Facebook rolls out AI to detect suicidal posts before
they’re reported. techcrunch.com 2017. https://techcrunch.com/2017/
11/27/facebook-ai-suicide-prevention/. Accessed 17 April 2019
51. Wilkinson MD, Dumontier M, Aalbersberg IJ et al (2016) The FAIR
guiding principles for scientific data management and stewardship. Sci
Data 3:160018
52. Gonzalez-Hernandez G, Sarker A, O’Connor K et al (2017) Capturing
the patient’s perspective: a review of advances in natural language
processing of health-related text. Year Med Inform 26:214–227
53. Freitas F, Schulz S, Moraes E (2009) Survey of current terminologies
and ontologies in biology and medicine. RECIIS-Electronic J Comm
Inform Innov Health 3:7–18
54. Schulz S, Jansen L (2013) Formal ontologies in biomedical
knowledge representation. Yearb Med Inform 8:132–146
55. Zeng QT, Goryachev S, Weiss S, Sordo M, Murphy SN, Lazarus R
(2006) Extracting principal diagnosis, co-morbidity and smoking
status for asthma research: evaluation of a natural language processing
system. BMC Med Inform Decis Mak 6:30
56. Stelzl U (2013) Molecular interaction networks in the analyses of
sequence variation and proteomics data. Proteomics Clin Appl
7:727–732
57. Woodsmith J, Stelzl U (2017) Understanding disease variants through
the lens of protein interactions. Cell Syst 5:544–546
58. Gonçalves E, Fragoulis A, Garcia-Alonso L, Cramer T, Saez-
Rodriguez J, Beltrao P (2017) Widespread post-transcriptional
attenuation of genomic copy-number variation in cancer. Cell Syst
5:386–398
59. Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, del Castillo
Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M,
Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao
P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-
Rodriguez J, McDermott U, Choudhary JS (2017) Genomic determi-
nants of protein abundance variation in colorectal cancer cells. Cell
Rep 20:2201–2214
60. Shendure J, Fields S (2016) Massively parallel genetics. Genetics
203:617–619
61. Woodsmith J, Apelt L, Casado-Medrano V, Özkan Z, Timmermann
B, Stelzl U (2017) Protein interaction perturbation profiling at amino-
acid resolution. Nat Methods 14:1213–1221
62. Freedman LP, Inglese J (2014) The increasing urgency for standards
in basic biologic research. Cancer Res 74:4024–4029
63. Freedman LP, Cockburn IM, Simcoe TS (2015) The economics of
reproducibility in preclinical research. PLoS Biol 13:e1002165
64. Simeon-Dubach D, Perren A (2011) Better provenance for biobank
samples. Nature 475:454–455
65. Mayrhofer MT, Holub P, Wutte A, Litton JE (2016) BBMRI-ERIC:
the novel gateway to biobanks . Bundesgesundhei tsb l
Gesundheitsforsch Gesundheitsschutz 59:379–384
66. Haslacher H, Szekeres T, Gerner M et al (2017) The effect of storage
temperature fluctuations on the stability of biochemical analytes in
blood serum. Clin Chem Lab Med 55:974–983
67. Chaigneau C, Cabioch T, Beaumont K, Betsou F (2007) Serum
biobank certification and the establishment of quality controls for
biological fluids: examples of serum biomarker stability after
temperature variation. Clin Chem Lab Med 45:1390–1395
68. Malentacchi F, Ciniselli CM, Pazzagli M, Verderio P, Barraud L, Hartmann
CC, Pizzamiglio S, Weisbuch S, Wyrich R, Gelmini S (2015) Influence of
pre-analytical procedures on genomic DNA integrity in blood samples: the
SPIDIA experience. Clin Chim Acta 440:205–210
69. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J,
Herdman C, Bankaitis-Davis D, Nicholls N, Trollinger D, Tryon V
(2002) Stabilization of mRNA expression in whole blood samples.
Clin Chem 48:1883–1890
70. Malentacchi F, Pazzagli M, Simi L, Orlando C, Wyrich R, Günther K,
Verderio P, Pizzamiglio S, Ciniselli CM, Zhang H, Korenková V,
Rainen L, Bar T, Kubista M, Gelmini S (2014) SPIDIA-RNA: second
external quality assessment for the pre-analytical phase of blood
samples used for RNA based analyses. PLoS One 9:e112293
71. Gündisch S, Hauck S, Sarioglu H, Schott C, Viertler C, Kap M,
Schuster T, Reischauer B, Rosenberg R, Verhoef C, Mischinger HJ,
Riegman P, Zatloukal K, Becker KF (2012) Variability of protein and
phosphoprotein amounts in clinical tissue specimens during the
preanalytical phase. J Proteome Res 11:5748–5762
72. Bernini P, Bertini I, Luchinat C, Nincheri P, Staderini S, Turano P
(2011) Standard operating procedures for pre-analytical handling of
blood and urine for metabolomics studies and biobanks. J Biomole
NMR 49:231–243
73. Kaushik N, Green S (2014) Pre-analytical errors: their impact and how
to minimize them. Med Lab Observ 46:22–26
74. Regulation (EU) 2017/746 of the European Parliament and of the
Council of 5 April 2017 on in vitro diagnostic medical devices and
repealing Directive 98/79/EC and Commission Decision 2010/227/EU
(https://eur-lex.europa.eu/eli/reg/2017/746/oj)
75. Paltiel L, Aarem J, Bækken S et al (2012) Biospecimen quality
program in the biobank of the Norwegian Institute of Public Health.
Norsk Epidemiol 21:225–229
Lim M.S. et al.: Advancing Biomarker Development Through Convergent Engagement
76. Lippi G, Chance JJ, Church S, Dazzi P, Fontana R, Giavarina D,
Grankvist K, Huisman W, Kouri T, Palicka V, Plebani M, Puro V,
Salvagno GL, Sandberg S, Sikaris K, Watson I, Stankovic AK,
Simundic AM (2011) Preanalytical quality improvement: from dream
to reality. Clin Chem Lab Med 49:1113–1126
77. Plebani M (2006) Errors in clinical laboratories or errors in laboratory
medicine? Clin Chem Lab Med 44:750–759
78. Lippi G, Guidi GC, Mattiuzzi C, Plebani M (2006) Preanalytical
variability: the dark side of the moon in laboratory testing. Clin Chem
Lab Med 44:358–365
79. Grecu DS, Vlad DC, Dumitrascu V (2014) Quality indicators in the
preanalytical phase of testing in a stat laboratory. Lab Med 45:74–81
80. Zaini R, Dahlawi HA, Siddiqi A (2016) Identification of the types and
frequencies of pre-analytical errors in the clinical biochemistry
laboratory: 1-year study at Hera’a General Hospital. Archiv Med 8:1
81. Kamlage B, Neuber S, Bethan B et al (2018) Impact of prolonged
blood incubation and extended serum storage at room temperature on
the human serum metabolome. Metabolites 8:pi:E6
82. Yang W, Chen Y, Xi C, Zhang R, Song Y, Zhan Q, Bi X,
Abliz Z (2013) Liquid chromatography-tandem mass
spectrometry-based plasma metabonomics delineate the effect
of metabolites’ stability on reliability of potential biomarkers.
Anal Chem 85:2606–2610
83. Kamlage B, Maldonado SG, Bethan B, Peter E, Schmitz O,
Liebenberg V, Schatz P (2014) Quality markers addressing
preanalytical variations of blood and plasma processing identified by
broad and targeted metabolite profiling. Clin Chem 60:399–412
84. Adams GP, Weiner LM (2009) Monoclonal antibody therapy of
cancer. Nat Biotechnol 9:1147–1157
85. Hofmann M, Große-Hovest L, Nübling T, Pyż E, Bamberg ML,
Aulwurm S, Bühring HJ, Schwartz K, Haen SP, Schilbach K,
Rammensee HG, Salih HR, Jung G (2012) Generation, selection and
preclinical characterization of an Fc-optimized FLT3 antibody for the
treatment of myeloid leukemia. Leukemia 26:1228–1237
86. Nelson MH, Paulos CM (2015) Novel immunotherapies for hemato-
logic malignancies. Immunol Rev 263:90–105
87. Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris
K, Szot C, Morris H, Swing DA, Tessarollo L, Smith SW, Degrado S,
Borkin D, Jain N, Scheiermann J, Feng Y, Wang Y, Li J, Welsch D,
DeCrescenzo G, Chaudhary A, Zudaire E, Klarmann KD, Keller JR,
Dimitrov DS, St. Croix B (2017) Eradication of tumors through
simultaneous ablation of CD276/B7-H3-positive tumor cells and
tumor vasculature. Cancer Cell 31:501–515
88. Hemminki A, Kellokumpu-Lehtinen PL (2006) Harmful impact of EU
clinical trials directive. BMJ 332:501–502
89. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S,
Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C (2017) Role of
tumor microenvironment in tumorigenesis. J Cancer 8:761–773
90. Crotti S, Piccoli M, Rizzolio F, Giordano A, Nitti D, Agostini M
(2017) Extracellular matrix and colorectal cancer: how surrounding
microenvironment affects cancer cell behavior? J Cell Physiol
232:967–975
91. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune
cells in the tumor microenvironment. Nat Immunol 14:1014–1022
92. Guldbrandsen KF, Hendel HW, Langer SW, Fischer B (2017) Nuclear
molecular imaging strategies in immune checkpoint inhibitor therapy.
Diagnostics 7:23
93. He JB, Hu Y, Hu MM, Li BL (2015) Development of PD-1/PD-L1
pathway in tumor immune microenvironment and treatment for non-
small cell lung cancer. Sci Rep 5:13110
94. Dong YN, Sun Q, Zhang XW (2017) PD-1 and its ligands are
important immune checkpoints in cancer. Oncotarget 8:2171–2186
95. Chatterjee S, Lesniak WG, Nimmagadda S (2017) Noninvasive
imaging of immune checkpoint ligand PD-L1 in tumors and
metas tases for guiding immunotherapy. Mol Imaging
16(1):536012117718459
96. Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A,
Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van
der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA,
Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers
AH, Fine BM, de Vries EGE (2018) 89Zr-atezolizumab imaging as a
non-invasive approach to assess clinical response to PD-L1 blockade
in cancer. Nat Med 24:1852–1858
97. Hammoud DA (2016) Molecular imaging of inflammation: current
status. J Nucl Med 57:1161–1165
98. Ponomarev V (2017) Advancing immune and cell-based therapies
through imaging. Mol Imaging Biol 19:379–384
99. Ebert PJR,Cheung J, YangY,McNamara E,HongR,MoskalenkoM,Gould
SE, Maecker H, Irving BA, Kim JM, Belvin M, Mellman I (2016) MAP
kinase inhibition promotes T cell and anti-tumor activity in combination with
PD-L1 checkpoint blockade. Immunity 44:609–621
100. Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G
(2016) High-resolution PET imaging with therapeutic antibody-
based PD-1/PD-L1 checkpoint tracers. Theranostics 6:1629–1640
101. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla
J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin
J, Liau LM, Prins RM (2017) Detection of immune responses after
immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad
Sci U S A 114:10220–10225
102. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy
N, Phelps ME, Witte ON (2008) Molecular imaging of lymphoid
organs and immune activation by positron emission tomography with
a new [18F]-labeled 2′-deoxycytidine analog. Nat Med 14:783–788
103. Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS,
Gambhir SS (2011) Synthesis of 2′-deoxy-2′-[18F]fluoro-9-beta-D-
arabinofuranosylguanine: a novel agent for imaging T-cell activation
with PET. Mol Imaging Biol 13:812–818
104. Tavare R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA,
Salazar FB, Witte ON, Ribas A, Wu AM (2016) An effective
immuno-PET imaging method to monitor CD8-dependent responses
to immunotherapy. Cancer Res 76:73–82
105. ClinicalTrials.gov. 89Zr-Df-IAB22M2C PET/CT in patients with
selected, metastatic solid malignancies or Hodgkin’s lymphoma.
https://clinicaltrials.gov/ct2/show/NCT03107663 (accessed
11.5.2018)
106. Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D,
Liu G, McNeel DG, Nickles RJ, Cai W (2017) ImmunoPET imaging
of CTLA-4 expression in mouse models of non-small cell lung
cancer. Mol Pharm 14:1782–1789
107. Zheleznyak A, Ikotun OF, Dimitry J, Frazier WA, Lapi SE (2013)
Imaging of CD47 expression in xenograft and allograft tumor
models. Mol Imaging 12:7290.2013.00069. https://doi.org/10.2310/
7290.2013.00069
108. Griessinger CM, Maurer A, Kesenheimer C, Kehlbach R, Reischl G,
Ehrlichmann W, Bukala D, Harant M, Cay F, Brück J, Nordin R,
Kohlhofer U, Rammensee HG, Quintanilla-Martinez L, Schaller M,
Röcken M, Pichler BJ, Kneilling M (2015) 64Cu antibody-targeting
of the T-cell receptor and subsequent internalization enables in vivo
tracking of lymphocytes by PET. Proc Natl Acad Sci U S A
112:1161–1166
109. Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, Straub
M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa
M, Schwaiger M, D’Alessandria C, Krackhardt AM (2016) Immuno-
PET imaging of engineered human T cells in tumors. Cancer Res
76:4113–4123
110. Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K,
Graner FP, Ettl J, Keller U, Wester HJ, Schwaiger M (2016) First
experience with chemokine receptor CXCR4-targeted PET imaging
of patients with solid cancers. J Nucl Med 57:741–746
111. Meletta R, Müller Herde A, Dennler P, Fischer E, Schibli R, Krämer
SD (2016) Preclinical imaging of the co-stimulatory molecules CD80
and CD86 with indium-111-labeled belatacept in atherosclerosis.
EJNMMI Res 6:1
112. Betzel T, Muller C, Groehn V et al (2013) Radiosynthesis and
preclinical evaluation of 3′-Aza-2′-[18F]fluorofolic acid: a novel PET
radiotracer for folate receptor targeting. Bioconjug Chem 24:205–
214
113. Ayala-Lopez W, Xia W, Varghese B, Low PS (2010) Imaging of
atherosclerosis in apoliprotein E knockout mice: targeting of a folate-
conjugated radiopharmaceutical to activated macrophages. J Nucl
Med 51:768–774
114. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting:
integrating immunity’s roles in cancer suppression and promotion.
Science 331:1565–1570
115. Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with
mismatch-repair deficiency. N Engl J Med 372:2509–2520
Lim M.S. et al.: Advancing Biomarker Development Through Convergent Engagement
116. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM,
Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann
TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison
CT, Wang L, Ribas A, Wolchok JD, Chan TA (2014) Genetic basis
for clinical response to CTLA-4 blockade in melanoma. N Engl J
Med 371:2189–2199
117. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp
A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S,
Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R,
Brahmer JR, KEYNOTE-024 Investigators (2016) Pembrolizumab
versus chemotherapy for PD-L1-positive non-small-cell lung cancer.
N Engl J Med 375:1823–1833
118. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell
S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB,
Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM,
Rodig S, Roemer MGM, Ligon AH, Engert A (2016) Nivolumab for
classical Hodgkin’s lymphoma after failure of both autologous stem-
cell transplantation and brentuximab vedotin: a multicentre,
multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283–1294
119. Bergmann M, Romirer I, Sachet M, Fleischhacker R, García-Sastre
A, Palese P, Wolff K, Pehamberger H, Jakesz R, Muster T (2001) A
genetically engineered influenza A virus with ras-dependent
oncolytic properties. Cancer Res 61:8188–8193
120. Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new
class of immunotherapy drugs. Nat Rev Drug Discov 14:642–662
121. Schork NJ (2015) Personalized medicine: time for one-person trials.
Nature 520:609–611
122. Bach PB (2009) Limits on Medicare’s ability to control rising
spending on cancer drugs. N Engl J Med 360:626–633
123. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance
GW (2015) Methods for the economic evaluation of health care
programmes, 4th edn. Oxford: Oxford University Press, Oxford
124. Soares MO, Walker S, Palmer SJ, Sculpher MJ (2018) Establishing
the value of diagnostic and prognostic tests in health technology
assessment. Med Decis Mak 38:495–508
125. Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C,
Soares M, Spackman E, Youn J (2012) Informing a decision
framework for when NICE should recommend the use of health
technologies only in the context of an appropriately designed
programme of evidence development. Health Technol Assess 16:1–
323
126. Drucker E, Krapfenbauer K (2013) Pitfalls and limitations in
translation from biomarker discovery to clinical utility in predictive
and personalised medicine. EPMA J 4:7
127. Salari K (2009) The dawning era of personalized medicine exposes a
gap in medical education. PLoS Med 6:e1000138
128. National Research Council (2011) Toward precision medicine:
building a knowledge network for biomedical research and a new
taxonomy of disease. The National Academies Press, Washington,
DC. https://doi.org/10.17226/13284
129. Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan
R, Emberton M, Sculpher MJ (2018) Optimising the diagnosis of
prostate cancer in the era of multi-parametric magnetic resonance
imaging: a cost-effectiveness analysis based on the Prostate MR
Imaging Study (PROMIS). Eur Urol 73:23–30
130. Pletscher M, Walker SM, Moschetti K, Pinget C, Wasserfallen JB,
Greenwood JP, Schwitter J, Girardin FR (2016) Cost-effectiveness of
functional cardiac imaging in the diagnostic work-up of coronary
heart disease. Eur Heart J Qual Care Clin Outcomes 2:201–207
131. Farrar D, Simmonds M, Griffin S, Duarte A, Lawlor DA, Sculpher
M, Fairley L, Golder S, Tuffnell D, Bland M, Dunne F, Whitelaw D,
Wright J, Sheldon TA (2016) The identification and treatment of
women with hyperglycaemia in pregnancy: an analysis of individual
participant data, systematic reviews, meta-analyses and an economic
evaluation. Health Technol Assess 20:1–348
132. Saramago P, Yang H, Llewellyn A, Palmer S, Simmonds M, Griffin
S (2018) High-throughput, non-invasive prenatal testing for fetal
RHD genotype to guide antenatal prophylaxis with anti-D immuno-
globulin: a cost-effectiveness analysis. BJOG 125:1414–1422
133. Ahn AC, Tewari M, Poon CS, Phillips RS (2006) The clinical
applications of a systems approach. PLoS Med 3:e209
134. Auffray C, Chen Z, Hood L (2009) Systems medicine: the future of
medical genomics and healthcare. Genome Med 1:2
135. Capobianco E (2012) Ten challenges for systems medicine. Front
Genet 3:193
136. Capobianco E (2013) Dynamic networks in systems medicine. Front
Genet 3:185
137. Federoff HJ, Gostin LO (2009) Evolving from reductionism to
holism: is there a future for systems medicine? JAMA 302:994–996
138. Fischer T, Brothers K, Erdmann P et al (2016) Clinical decision-
making and secondary findings in systems medicine. BMC Med
Ethics 17:32
139. Wolkenhauer O, Auffray C, Jaster R, Steinhoff G, Dammann O
(2013) The road from systems biology to systems medicine. Pediatr
Res 73:502–507
140. Zhao Z, Shen B, Lu X et al (2013) Translational biomedical
informatics and computational systems medicine. Biomed Res Int
2013:237465
141. Gomez-Cabrero D, Menche J, Cano I et al (2014) Systems medicine:
from molecular features and models to the clinic in COPD. J Transl
Med 12(Suppl 2):S4
142. Schleidgen S, Fernau S, Fleischer H, Schickhardt C, Oßa AK,
Winkler EC (2017) Applying systems biology to biomedical research
and health care: a précising definition of systems medicine. BMC
Health Serv Res 17:761
143. Howard SA, Krajewski KM, Weissman BN, Seltzer SE, Ramaiya
NH, van den Abbeele AD (2015) Cancer imaging training in the 21st
century: an overview of where we are, and where we need to be. J
Am Coll Radiol 12:714–720
144. Wang E, Cho WCS, Wong SCC, Liu S (2017) Disease biomarkers
for precision medicine: challenges and future opportunities. Geno-
mics Proteomics Bioinformatics 15:57–58
Publisher’s Note. Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Lim M.S. et al.: Advancing Biomarker Development Through Convergent Engagement
